20/20 Biolabs, Inc. (AIDX)
20/20 Biolabs, Inc. (ticker AIDX) is a publicly traded medical technology company focused on developing and commercializing advanced diagnostic imaging systems and services. The company specializes in ophthalmic and visual health technologies designed to improve patient outcomes through early detection and precision diagnostics in vision-related and broader medical applications.
What the company does
20/20 Biolabs develops diagnostic imaging platforms and related services, with emphasis on ophthalmic applications and broader visual health diagnostics. The company’s technology aims to support clinical decision-making and patient care through non-invasive imaging modalities and analysis tools. Its portfolio includes systems designed for use in clinical settings, diagnostic centers, and research environments.
How it makes money
The company generates revenue through multiple streams: the sale and deployment of diagnostic imaging equipment, service contracts for system maintenance and support, licensing of imaging technology and software platforms, and fees for diagnostic services delivered through its imaging systems. Revenue models typically combine equipment sales with recurring service and support arrangements, creating both upfront and ongoing revenue opportunities.
Where it sits in its industry
20/20 Biolabs operates in the competitive medical device and diagnostic imaging sector. The company competes with larger, established imaging manufacturers and diagnostic service providers while targeting niche and emerging applications in ophthalmic and visual health diagnostics. Its position centers on specialized technology, clinical partnerships, and the growing demand for non-invasive diagnostic tools that improve early detection and precision medicine.
How to research it
Investors and analysts can find detailed financial and operational information in the company’s 10-K annual reports and 10-Q quarterly filings with the SEC, available through the SEC’s EDGAR database using CIK 1139685. These documents disclose revenue breakdowns, operating expenses, research and development activities, clinical validations, competitive dynamics, and forward-looking statements. Press releases and investor relations materials provide updates on product launches, partnerships, and clinical achievements.